Results: Amazing Innovations in Medical Procedures
Johnson & Johnson (NYSE: JNJ) has made several major announcements and clinical updates:
1.
1.
FDA Approval: On November 5, 2026, the U.S. FDA granted accelerated approval to RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the first and only dual-targeted subcutaneous therapy for recurrent or metastatic head, neck and lung cancer (achieving a 42% overall response rate) Were you aware of this new break through?
Yes
8%
•
81 votes
No
68%
•
653 votes
Undecided
7%
•
67 votes
Not Applicable
17%
•
167 votes
2.
2.
Prostate Cancer Research: On November 8–9, 2026, J&J announced positive Phase 1 results at the SITC Annual Meeting for its investigational dual-antigen bispecific immunotherapy combination of pasritamig and JNJ-6143 which showed a 73% PSA response rate in patients with advanced prostate cancer. Were you aware of this new break through?
Yes
9%
•
85 votes
No
67%
•
644 votes
Undecided
7%
•
69 votes
Not Applicable
18%
•
170 votes
3.
3.
Psychedelic-Inspired Medicine Investment: On November 9, 2026, Bloomberg reported that Johnson & Johnson is backing Delix Therapeutics Inc. in a $100 million financing round to develop non-hallucinogenic, psychedelic-inspired pills for depression. Were you aware of this new break through?
Yes
9%
•
88 votes
No
67%
•
646 votes
Undecided
7%
•
66 votes
Not Applicable
17%
•
168 votes
Comments